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ORIGINAL ARTICLE
Citrullination of histone H3 drives IL-6 production by bone
marrow mesenchymal stem cells in MGUS and multiple
myeloma
G McNee1, KL Eales1, W Wei2, DS Williams2, A Barkhuizen3, DB Bartlett2, S Essex2, S Anandram3, A Filer4, PAH Moss4, G Pratt2,5, S Basu3,6,
CC Davies2,6 and DA Tennant1
Multiple myeloma (MM), an incurable plasma cell malignancy, requires localisation within the bone marrow. This microenvironment
facilitates crucial interactions between the cancer cells and stromal cell types that permit the tumour to survive and proliferate.
There is increasing evidence that the bone marrow mesenchymal stem cell (BMMSC) is stably altered in patients with MM—a
phenotype also postulated to exist in patients with monoclonal gammopathy of undetermined signiﬁcance (MGUS) a benign
condition that precedes MM. In this study, we describe a mechanism by which increased expression of peptidyl arginine deiminase
2 (PADI2) by BMMSCs in patients with MGUS and MM directly alters malignant plasma cell phenotype. We identify PADI2 as one of
the most highly upregulated transcripts in BMMSCs from both MGUS and MM patients, and that through its enzymatic deimination
of histone H3 arginine 26, PADI2 activity directly induces the upregulation of interleukin-6 expression. This leads to the acquisition
of resistance to the chemotherapeutic agent, bortezomib, by malignant plasma cells. We therefore describe a novel mechanism by
which BMMSC dysfunction in patients with MGUS and MM directly leads to pro-malignancy signalling through the citrullination of
histone H3R26.
Leukemia advance online publication, 12 August 2016; doi:10.1038/leu.2016.187
INTRODUCTION
Multiple myeloma (MM) is a malignant disease of plasma cells
within the bone marrow that, despite improving survival, remains
incurable meaning an urgent requirement for novel therapies.
One characteristic feature of MM is that a pre-malignant condition
known as monoclonal gammopathy of undetermined signiﬁcance
(MGUS) can be present for many years prior to development of
overt disease.1 No speciﬁc genetic alterations have yet been
identiﬁed that distinguish patients with MGUS from those with
MM, suggesting that another factor, such as transformation of the
microenvironment are likely drivers of progression.2,3 Malignant
plasma cells have an absolute requirement for localisation within
the bone marrow niche, which leads to a characteristic feature of
MM: the relative rarity of disease metastasis to sites outside the
marrow microenvironment. This suggests that, in common with
most malignancies, stromal support of cancer cell survival in MM is
important for maintaining and even driving disease.4–6
Key cellular components of both the normal and transformed
bone marrow niche are the bone marrow mesenchymal stem cells
(BMMSCs). There is now signiﬁcant evidence to suggest that
BMMSCs from patients with MM7–11 and MGUS7 are phenotypi-
cally different from those derived from healthy patients. Indeed
they have not only been shown to exhibit a stably altered
transcriptional proﬁle,7 but may also contain a number of genetic
lesions.12 The phenotypic changes resulting from this altered
transcriptome appear to permit increased stromal support of the
malignant plasma cell, and decreased osteoblastic differentiated
function (bone mineralisation).7–11 The former is through both
physical (that is, cell–cell) interactions, and secretion of a number
of paracrine factors that support malignant plasma cell survival,
proliferation, migration and chemoresistance.5,6,13 Although a
number of signalling pathways have been implicated in the
differentiation of BMMSCs there remains a lack of clarity as to
their role.
A number of cytokines and chemokines have been shown to be
involved in the cross-talk between the bone marrow stroma and
malignant plasma cells, including interleukin-6 (IL-6),14 C-X-C motif
chemokine 12 (CXCL12, also known as stromal-derived factor 1),15
vascular endothelial growth factor (VEGF),16 ﬁbroblast growth
factor,17 tumour necrosis factor α,18 interleukin-1β18 and cMET
(also known as hepatocyte growth factor/scatter factor).19 IL-6
secretion by the cells of bone marrow microenvironment,
especially the BMMSC population,7,9,11 has been shown to have
a role in malignant plasma cell phenotype through increasing
resistance to cell death stimuli and driving proliferation,20 as well
as downregulating differentiation markers, such as CD38 and
CD138.21 It is therefore now clear that through both physical
association and paracrine interactions, signalling between
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BMMSCs and myeloma cells underlies the requirement of
myeloma cells for BM localisation.
One deﬁning feature of BMMSCs isolated from patient bone
marrows is that they retain a transcriptomic proﬁle despite being
in culture.7–9,11,21 This suggests that they sustain this transcrip-
tome through a stable genetic and/or epigenetic proﬁle. Interest-
ingly, little is known about the epigenetic status of BMMSCs in
healthy individuals or of those from MGUS or MM patients. A post-
translational modiﬁcation in which there is increasing interest in
both cancer and inﬂammation is the citrullination of peptidyl
arginine, which can occur on many different protein species,
including histones.22 These reactions are performed by the
calcium-dependent peptidyl arginine deiminase (PADI) family of
enzymes of which there are ﬁve members (PADI1, 2, 3, 4 and 6)
with tissue-speciﬁc expression patterns.23–25 Peptidyl arginine
deiminase 2 (PADI2) is ubiquitously expressed, and in many tissues
has been reported as the major family member providing peptidyl
arginine deiminase activity.26 Importantly, both PADI2 and PADI4
have been shown to be able to alter gene transcription through
the citrullination of residues in the histone tails:27–29 a modiﬁca-
tion that may be physiologically irreversible owing to the lack of
any known peptidylcitrulline imidating enzyme. This modiﬁcation
is therefore a good candidate for the creation of a long-term
change in the cellular transcriptome, as noted in the BMMSCs of
MM patients.
As MM is effectively incurable, and is now accepted to almost
always arise from MGUS,1 the phenotype of cells contributing to
this benign condition may provide important clues as to factors
determining progression to MM. We show here that BMMSCs from
patients with both MGUS and MM exhibit a signiﬁcant shift in their
transcriptome compared with those from healthy individuals. In
addition, we demonstrate that one of the most upregulated
transcripts in BMMSCs from MGUS and MM, PADI2 is responsible
for mediating increased IL-6 expression from these cells through
the deimination of arginine residue 26 of histone H3 (H3R26) to
form citrulline (H3R26cit). This increased IL-6 production is
sufﬁcient to drive resistance of malignant plasma cells to
bortezomib, a highly clinically relevant anti-myeloma drug. We
therefore demonstrate a novel mechanism for BM microenviron-
ment-induced acquisition of drug resistance in MM and impor-
tantly, that this phenotype is already present in patients with the
apparently benign MGUS.
MATERIALS AND METHODS
Patient sample collection, BMMSC isolation and cell culture
Patients with MM and MGUS were recruited from specialist clinics at The
Royal Wolverhampton Hospitals NHS Trust and Heart of England NHS Trust,
UK. The study received approval from the local ethics committees at South
Birmingham, Birmingham East, North, and Solihull, and informed written
consent was obtained in accordance with the Declaration of Helsinki in all
cases. For patients with MGUS/MM, BM aspirates from the iliac crest were
diluted in MACS buffer for removal of the CD138+ cells using anti-CD138+
antibody-linked magnetic beads (Miltenyi Biotech, Bisley, UK), before the
remaining cellular fraction was diluted in complete medium, and BMMSCs
allowed to adhere to tissue culture plates. Control BMMSCs for the
transcriptomic study were obtained by ﬂushing out a section of rib from
patients undergoing thoracotomies with Rosewell Park Memorial Institute
(RPMI) 1640 medium (Sigma, Gillingham, UK). Around 80% of the patients
recruited to this control group had a primary lung tumour: none had bone
marrow involvement or had received chemotherapy. Patient number and
characteristics for the transcriptomic study are shown in Supplementary
Table 1, whereas those of the BMMSCs used in all other studies are shown
in Supplementary Table 2. For the other studies, ‘healthy’ BMMSCs were
isolated from patients undergoing hip surgery, with informed written
consent obtained and samples collected through the University of
Birmingham Research Tissue Bank (HTA license 12358, REC reference 09/
H1010/75). Bone marrow aspirates from the femoral head were diluted in
RPMI1640 and the BMMSCs in the non-fatty layer allowed to adhere to
tissue culture plates. BMMSCs and the HS5 human bone marrow ﬁbroblast
cell line (ATCC CRL11882, LGC Standards, Teddington, UK, purchased
December 2013, tested for mycoplasma every 3 months by PCR) were
cultured in RPMI1640 medium with 10% fetal bovine serum (Hyclone, GE
Healthcare, Little Chalfont, UK) at 37 1C in a humidiﬁed incubator with 5%
CO2. BMMSCs were allowed to adhere and proliferate to ~ 80% conﬂuence
before harvesting. Wild-type or active-site mutant PADI2 (C647S), each
with N-terminal FLAG tag, were expressed through transient transfection
of the complementary DNAs within the pcDNA3 vector (or empty vector
control) using jetPEI (Polyplus transfection, Illkirch, France) for 24 h before
analysis. Where shown, the pan-PADI inhibitor Cl-Amidine (200 μM,
Caymen Chemical, Ann Arbor, MI, USA) was used for 48 or 72 h. Small
interfering (siRNA) against PADI2 at 20 nM (Oligo 1: AGCCTTG
ACTCATTTGGAA, and Oligo 4: AAGCGAATCACCATCAACA) or PADI4 (GCG
AAGACCTGCAGGACAT) were transfected using TransIT-TKO (Mirus Bio,
Madison, WI, USA) and assayed at the time point shown.
Transcriptomic and Real-time PCR analyses
At passage 3, mRNA from BMMSCs (Supplementary Table 1) was extracted
using the RNeasy mini kit (Qiagen, Düsseldorf, Germany). mRNA was
prepared and hybridised to Affymetrix HuEx-1_0-st-v2 exon arrays
(Affymetrix, Santa Clara, CA, USA) as per manufacturer’s instructions. Gene
level analysis of the Affymetrix exon array was performed using Affymetrix
Expression Console with the default settings of ‘Extended: RMA-Sketch’
and Affymetrix annotation na32. Differentially expressed genes were
identiﬁed using the limma package30 with cutoff values of Po0.001
and absolute fold change41.5. Heatmaps were generated using dChip
(http://www.dchip.org/) with the default settings. Full data set is available
in the Gene Expression Omnibus repository with accession number
GSE80608. For Taqman analyses, RNA was isolated using the RNeasy kit
before reverse transcription (AMV reverse transcription kit, Promega,
Southampton, UK). Taqman real-time PCR was performed on an ABI7500;
using primer/probe mixes (Supplementary Table 3, Life Technologies,
Inchinnan, UK). Cycle threshold was automatically determined by ABI7500
software and expression levels were normalised to ACTB and calculated
relative to control. All transcript data are presented as median-centred box
and whisker (10–90th percentile) plots.
Detection of apoptosis by ﬂow cytometry
Primary BMMSCs from MGUS patients that showed high or low PADI2
protein levels (Supplementary Table 2) were seeded at 5 × 105 cells 24 h
before 106 JJN3 cells were added to a TransWell insert (Costar Appleton
Woods, Birmingham, UK), 24 h prior to treatment with 10 nM bortezomib.
After a further 24 h, JJN3 cell apoptosis was assessed by Annexin
V/propidium iodide staining as per manufacturer’s instructions (Life
Technologies) and ﬂow cytometry (LSRII; BD Biosciences, Oxford, UK).
The resulting data were gated and quantiﬁed (Flow Jo v.7.6.5) and
presented after subtraction of background apoptosis of untreated,
monocultured JJN3 cells. Where shown, BMMSCs were treated with
Cl-Amidine (200 μM, 16 h), which was removed before washing and
subsequent incubation with JJN3 cells (within the TransWell insert).
Experiments were performed three times and expression analysed in
triplicate; data presented as mean± s.e.m.
Measurement of IL-6
HS5 cell culture supernatants were harvested after treatment with either
Cl-Amidine or siRNA and centrifuged to remove dead cells. Supernatants
were analysed using an IL-6 detection kit as per manufacturer’s
instructions (eBioscience, Altrincham, UK). Experiments were performed
three times in triplicate; data are presented as mean± s.d. IL-6 from BM
plasma was detected using a multiplex bead analysis approach
(Affymetrix). Measurements were performed as per manufacturer’s
instructions. In brief, plasma samples, diluted with an equal volume of
phosphate-buffered saline, pH7.4, were incubated with monoclonal
antibody-coated capture beads for 1 h at 20 °C. Washed beads were
further incubated with biotin-labelled polyclonal anti-human cytokine
antibody for 30 min, streptavidin–phycoerythrin for 30 min and analysed
on a Luminex 100 bioanalyser (Luminex, Ballina, Ireland) and converted to
absolute concentrations using standard curves. Data are presented as
median-centred box and whisker (10–90th percentile) plots.
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Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as previously described.31
In brief, HS5 ﬁbroblasts were cross-linked with 1% formaldehyde before
neutralisation with 0.125 M glycine. After lysis (10 mM Tris-HCl, pH8.0,
10 mM NaCl, 0.2% NP-40, 10 mM sodium butyrate, 50 μg/ml phenylmethyl-
sulfonyl ﬂuoride and 1 μg/ml leupeptin), nuclei were puriﬁed, lysed (50 mM
Tris-HCl, pH8.1, 10 mM ethylenediaminetetraacetic acid, 1% sodium
dodecyl sulphate, 10 mM sodium butyrate, 50 μg/ml phenylmethylsulfonyl
ﬂuoride and 1 μg/ml leupeptin) and diluted in immunoprecipitation buffer
(20 mM Tris-HCl, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 1%
Triton X-100, 0.01% sodium dodecyl sulphate, 10 mM sodium butyrate,
50 μg/ml phenylmethylsulfonyl ﬂuoride and 1 μg/ml leupeptin). DNA was
sheared to 300–1000 bp, and diluted further in immunoprecipitation
buffer. After pre-clearing (normal rabbit immunoglobulin G), chromatin
was co-immunoprecipitated with anti-histone H3 trimethyl K4 (Abcam,
Cambridge, UK, ab8580) or anti-histone H3 cit26 (Abcam; ab19847, lot
GR146412-1). After washing and elution of protein-DNA complexes from
the beads (100 mM NaHCO3, 1% sodium dodecyl sulphate), cross-links were
reversed by heating, and treated with proteinase K. DNA was puriﬁed;
primers used to quantify DNA are shown in Supplementary Table 4.
Experiments were performed three times and PCR performed in triplicate;
data presented as mean± s.e.m.
Western blotting
Samples were harvested, washed in phosphate-buffered saline and after
pelleting, lysed directly in lysis buffer (10 mM HEPES/KOH pH7.4, 10 mM KCl,
0.05% NP-40, 1 mM sodium orthovanadate). After centrifugation of the
lysate, the supernatant containing the cytoplasmic components was
retained, and the pelleted nuclei were washed with lysis buffer before
extraction of the nucleoplasmic protein fraction in low salt lysis buffer
(10 mM TRIS/HCl pH7.4, 0.2 mM MgCl2). After blocking, membranes were
probed with antibodies against actin (AC-40; Sigma), R26cit (ab19847;
Abcam), R2,8,17cit (ab5103; Abcam), PADI2 (ab16478; Abcam) or PADI4
(ab128086; Abcam), followed by the appropriate horseradish peroxidase-
linked secondary antibody (Cell Signalling, NEB, Hitchin, UK) and visualised
using ECL Prime (GE Healthcare, Amersham, UK).
Statistics
Sample size for patient studies could not be pre-determined because of
the lack of similar data on healthy and MGUS populations. No samples
were excluded from analyses presented. Error bars are shown for all data
presented. All statistics were performed using GraphPad Prism v.6.07. In
order to compare different patient groups without assumptions of data
distribution, non-parametric tests were used (Mann–Whitney and Kruskal–
Wallis) with Dunn’s post test comparisons where appropriate. Where
statistical tests were used on data from cell culture experiments, student’s
two-tailed t-tests with Welch’s correction were used to avoid assumptions
of variance between groups.
RESULTS
There is strong evidence to suggest that BMMSCs from patients
with MM show a transformed phenotype: supporting malignant
plasma cell survival, proliferation, and evasion of chemotherapy-
mediated cell death.7–11 The BMMSC phenotype in MGUS patients
is less-well characterised.7 We therefore performed a transcrip-
tomic analysis of mRNA extracted from BMMSCs cultured from
controls, MGUS and MM patients. BMMSCs isolated from patients
with both MGUS and MM show markedly different gene
expression proﬁles compared with the controls (Figure 1, cutoffs
used, Po0.001, fold change 1.5), consistent with the previous
report.7 Although a large number of transcripts were found to be
differentially expressed between controls and MGUS (91) or MM
Figure 1. Heatmap of transcriptomic analysis from 30 BMMSC
samples, 10 each from control, MGUS and MM patients shows that
cells from patients with MGUS and MM cluster together, and are
different from those isolated from healthy individuals. One hundred
and eighty seven genes were identiﬁed with a cutoff for gene
expression change of greater than 1.5-fold, and Po0.001.
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(117; cutoff Po0.001, fold change of42.0; Supplementary Tables
5 and 6), none were found to vary between MGUS and MM using
the same statistical cutoffs, and only 32 if these were relaxed
(cutoff of Po0.01, fold change of 41.3; Supplementary Table 7).
Pathway analysis of differentially expressed genes between
disease and control groups demonstrated that the most
prominent enriched signalling pathway was WNT (P= 0.00012
and 0.00002 for MM vs control and MGUS vs control, respectively;
Supplementary Tables 8 and 9 and Supplementary Figure 1a),
which has been previously implicated in the pathogenesis of
MM.32–34 In addition, within the top ﬁve upregulated transcripts in
MGUS and MM was a member of the PADI family of enzymes,
PADI2 (Figure 2a), which was upregulated over ﬁvefold in both
MGUS and MM patient BMMSCs. Importantly, two other function-
ally related transcripts were also in the top ﬁve; ﬁlaggrin, a well-
described target of PADI2 (Figure 2b), and SLC14A1, which
encodes the urea transporter required for excretion of ammonium
produced through PADI2 activity (Figure 2c, Supplementary
Figure 1b). Interestingly, we recently published evidence that
urea concentrations are signiﬁcantly increased in the bone
marrow plasma of patients with both MGUS and MM, consistent
with signiﬁcantly increased cellular production of ammonium,
perhaps through PADI2 activity, in the bone marrow niche.35
To conﬁrm the increased expression of PADI2 in BMMSCs in
MGUS and MM, we assessed both mRNA and protein expression in
BMMSCs isolated from an independent cohort of healthy
individuals, MGUS and MM patients (Supplementary Table 2).
We found that mRNA expression of PADI2 was relatively low in
BMMSCs from healthy patients (Figure 2d), corresponding with an
almost undetectable protein expression (Figure 2e). However, in
BMMSCs from MGUS or MM patients, expression of PADI was
greatly increased (Figures 2d and e): indeed mRNA expression was
increased 430-fold. Corresponding mRNA expression of other
PADI family members was unchanged (Supplementary Figure 2).
We therefore assessed the activity of PADI2 through its
citrullination of a recently described target: histone H3R26cit.27
We found that this modiﬁcation of histone H3 was signiﬁcantly
increased in BMMSCs from MGUS and MM compared to healthy
individuals (Figure 2e), where it was almost universally absent. In
contrast, citrullination of other arginine residues in histone H3 that
represent more speciﬁc PADI4 targets (R2, R8 and R17) were not
upregulated to the same extent, suggesting that PADI2 activity,
rather than PADI4 was likely to be responsible for H3R26cit levels
observed.
BMMSCs have been shown to play an important role in the
support of malignant plasma cell survival, proliferation and
resistance to chemotherapy.36 We therefore hypothesised that
increased expression of PADI2 may alter the ability of the BMMSC
to perform this function. We had previously noted that within the
primary BMMSCs we isolated from MGUS and MM patients, some
had relatively low expression of PADI2, whereas others were
higher. We therefore selected two lines each of ‘low’ and ‘high’
expressers (Figure 2e, MGUS samples 2 and 5 (low) or 3 and 4
(high), Supplementary Table 2), and co-cultured these with JJN3
cells, a myeloma cell line, using a TransWell system for 24 h before
treatment with the clinically relevant chemotherapeutic agent,
bortezomib. Although physically separate, the two cell lines could
interact through metabolic or secreted factor interactions. We
found that although co-culture with low PADI2-expressing
BMMSCs had little effect on JJN3 cell viability after bortezomib
treatment, high PADI2-expressing BMMSCs resulted in a signiﬁ-
cant protection, reducing the cell death induced by ~ 75%
(Figure 3a). Interestingly, pre-incubating the high PADI2-
expressing BMMSCs with the pan-PADI inhibitor Cl-Amidine
before co-culture with JJN3 cells led to a signiﬁcant increase in
bortezomib-induced apoptosis of the JJN3 cells (Figure 3b). These
data overall suggested that at least part of the protection from
chemotherapy-induced apoptosis elicited by BMMSCs was
through a PADI2-mediated event. It had previously been shown
that IL-6 production in the bone marrow microenvironment is
Figure 2. (a) Three of the top ﬁve upregulated transcripts that differed between control and ‘disease’ (MGUS/MM) BMMSCs identiﬁed from the
transcriptomic analysis were the peptidyl arginine deiminase, PADI2 (a), ﬁlaggrin (b) and the urea transporter, SLC14A1 (c). (d) PADI2 mRNA
expression in BMMSCs from controls, MGUS and MM patients compared with beta-actin, analysed using Taqman, plotted on a logarithmic
scale. Signiﬁcant changes shown were calculated using Mann–Whitney tests. *Po0.05, **Po0.005, ****Po0.0001. (e) BMMSCs derived from
patients with MGUS and MM have greatly increased expression of PADI2 and citrullination of histone H3 on residue R26 (R26cit) compared
with healthy controls. Citrullination of other arginine residues on histone H3 (R2,8,17) under the control of PADI4 are not similarly consistently
increased. ‘CL’ and ‘CH’ indicate control samples (CL: low expressing, CH: high expressing) analysed on each blot in order for blots to be more
easily compared.
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important for the acquisition of resistance phenotypes by the
plasma cells,20,37,38 with evidence for a role in bortezomib-induced
resistance.39 We therefore investigated IL-6 expression by
BMMSCs, and observed signiﬁcant increased transcription of IL-6
mRNA (Figure 3c), which led to enhanced secretion into the
medium from primary cells from patients with MGUS and MM
(Figure 3d). In addition, when mRNA expression of IL-6 was plotted
against that of PADI2, we found that they were positively
correlated (Figure 3e), providing further evidence for a mechan-
istic link between these two factors in MGUS and MM.
Using an immortalised, non-transformed BMMSC line (HS5), we
assessed the effect of siRNA-mediated reduction in PADI2
expression (Figure 4a) on the expression of IL-6, as well as other
factors expressed by BMMSCs known to have a role in MM
pathogenesis: CXCL12 and cMET. We found that expression of all
three pro-malignant factors was decreased when PADI2 expres-
sion was reduced, or PADI activity was inhibited by Cl-Amidine
(Figure 4b). Importantly, siRNA of PADI4 (Figure 4a) did not affect
expression of any of these factors, showing that this effect was
speciﬁcally through modulation of PADI2 expression (Figure 4b).
Expression of another important factor in the pathogenesis of MM,
VEGF, was not found to be modulated by PADI2 or PADI4
expression (Supplementary Figure 3). We directly tested the effect
of knocking down or inhibiting PADI2 on IL-6 secretion into the
medium of HS5 cells through siRNA or Cl-Amidine treatment, and
found that IL-6 was reduced in both conditions, and not further
reduced by combining both siRNA and inhibitor (Figure 4c),
further supporting our ﬁndings that PADI2 is the main PADI family
member that regulates IL-6 expression in BMMSCs. Finally, we
overexpressed PADI2 and found that IL-6 mRNA expression was
increased 10-fold (Figure 4d), whereas expression of an active-site
mutant of PADI2, C647S,40 had no effect (Figure 4d). These data
therefore provide direct mechanistic link between the expression
of PADI2 and increased IL-6 production in BMMSCs from MGUS/
MM patients.
It has previously been shown that PADI2 activity can citrullinate
the R26 residue of histone H3 (H3R26cit), resulting in increased
transcription of a number of genes.27 Our data also showed
increased levels of this modiﬁcation in BMMSCs from MGUS and
MM (Figure 2e). We therefore hypothesised that the mechanism
by which PADI2 activity could modulate transcription from the IL-6
locus was through increasing citrullination of H3R26 in its
promoter. Primer pairs that covered the IL-6 promoter region
were designed (Figure 5a), and a chromatin immunoprecipitation
experiment performed, in which after either siPADI2 or Cl-Amidine
treatment, antibodies against H3R26cit and trimethylated K4 of
Figure 3. (a) Expression of PADI2 protects plasma cells from chemotherapy-induced apoptosis. JJN3 cell apoptosis as a percentage of total
cells, either untreated (‘JJN3’), or 24 h after treatment with 10 nM bortezomib (‘+BTM’). When co-cultured with either a low PADI2-expressing
(‘PADI2 low’) or high PADI2-expressing (‘PADI2 High’) BMMSCs across a Boyden chamber, JJN3 cells are partially protected from bortezomib-
induced apoptosis, with extent of protection correlating with PADI2 expression. Two primary BMMSC lines were used per assay, each repeated
n= 3. Data were analysed by Kruskal–Wallis test (Po0.0001), with Dunn’s multiple comparisons test to test for those values that were
signiﬁcantly different. Error bars show s.d. (b) Inhibition of total PADI activity in the PADI2 High expressing lines using the pharmacological
inhibitor, Cl-Amidine (‘CL’) signiﬁcantly reduces acquired protection from bortezomib. Data were analysed using Mann–Whitney test, error
bars show s.d. **P= 0.002 (c) IL-6 expression is signiﬁcantly increased in BMMSCs derived from patients with MGUS and MM compared with
controls. IL-6 mRNA expression was normalised to beta-actin. Signiﬁcant changes shown between groups were calculated using
Mann–Whitney tests. ****Po0.0001. Error bars indicate 10th-90th percentile (d) Bone marrow concentrations of IL-6 are also increased in
patients with MGUS and MM. Mann–Whitney tests were again used to calculate signiﬁcance of differences between groups. ***P= 0.0005,
****Po0.0001. (e) Scatterplot of the expression of PADI2 against IL-6 as measured in BMMSCs from 38 patients with MM and MGUS shows
that their expression is highly correlated (r2= 0.540, non-linear ﬁt).
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histone H3 (H3K4me3) were used to pull-down chromatin
associated with these modiﬁcations. H3K4me3, a modiﬁcation
associated with active areas of chromatin, was used as a positive
control to determine whether changes in expression altered the
overall activation state of the chromatin. We found that both Cl-
Amidine (Figure 5b) and siPADI2 (Figure 5d) decreased the
enrichment of H3R26cit in the IL-6 promoter region, the effects of
which were particularly pronounced at and downstream of the
transcription start site (TSS; Figure 5a). This correlated with a loss
of the activating histone mark, H3K4me3 in the same conditions
(Cl-Amidine; Figure 5c, siPADI2; Figure 5e), indicating reduced
activation of the IL-6 promoter locus as a result of reduced PADI2
activity.
Our data therefore show that PADI2 expression correlates with
IL-6 expression in primary BMMSCs from patients with MGUS and
MM (Figure 3) as well as citrullination of the H3R26 (Figure 2e) in
the same cells. In addition, we have shown that PADI2 expression
can directly increase IL-6 expression (Figure 4) through
citrullination of the R26 residue of histone H3 in the promoter
region of the gene (Figure 5). Finally, we show that PADI2
expression and activity in BMMSCs can modulate malignant
plasma cell resistance to the chemotherapeutic agent, bortezomib
(Figures 3a and b, and Figure 6).
DISCUSSION
MM is an incurable disease that arises from the pre-malignant
condition MGUS, present in the bone marrow of up to 7.5% of the
elderly population.1,41,42 With increasing life expectancies and the
resulting shift in the demographics of most developed countries,
this disease represents a signiﬁcant clinical challenge. Although it
is now clear that the BM microenvironment is transformed in
patients with MM, there are few data concerning the nature of the
MGUS microenvironment. We demonstrate here that BMMSCs
from patients with both MGUS and MM have a transformed
transcriptome compared with those from healthy individuals, in
Figure 4. (a) Conﬁrmation of knockdown by siPADI2 by two independent siRNA sequences. (b) The expression of the BMMSC component of
critical chemokine signalling axes in myeloma (IL-6, CXCL12 and cMET) is modulated by PADI2 expression in the immortalised BMMSC cell line,
HS5. Expression of all three transcripts are reduced in response to reduction in PADI2 expression (siPADI2), or the addition of the pan-PADI
inhibitor, Cl-Amidine (200 μM, 72 h). However, siPADI4 does not alter expression of any of the transcripts. ** and *** indicate the level of
signiﬁcance assigned by a Dunn's comparison post-test after a signiﬁcant ANOVA for each dataset (Po0.0001 [IL-6]; P=0.0002 [CXCL12];
P=0.0019 [cMET]). (c) IL-6 expression, as measured through its secretion into the tissue culture medium by the HS5 cell line, is reduced after
treatment with Cl-Amidine and/or siPADI2. Data shown are mean of n= 3± s.d. *P= 0.039, unpaired student’s t-test with Welch’s correction.
(d) Overexpression of PADI2 increases IL-6 expression, whereas the catalytic mutant, C645S, does not increase expression over basal levels.
Data shown are mean of n= 3± s.d. **P= 0.004, unpaired student’s t-test with Welch’s correction.
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agreement with previous results.7 Our data, alongside those of
others and our previous metabolomic study35 highlight the
signiﬁcant similarities between the microenvironment of the BM
in MGUS and MM, suggesting that transformation of the BM
microenvironment is an early event in disease aetiology, raising
the potential of interfering with this process in order to delay or
prevent progression of patients with MGUS to MM. In addition,
these data further highlight a need to identify those biological
Figure 5. (a) Diagram showing the coverage of the IL-6 promoter region by the primer pairs used in the chromatin immunoprecipitation analysis.
Pull-down of chromatin associated with either citrullinated R26 (b, d) or trimethylated K4 (c, e) of histone H3, show that both inhibition of PADI
activity by Cl-Amidine (b, c) and reduction of PADI2 expression (through siRNA, d, e) reduce the enrichment of these marks on and downstream
of the IL-6 transcription start site, indicating that PADI2 activity is required for full activation of transcription from this locus. For all panels, error
bars are ± s.e.m.
Figure 6. Model of how PADI2 activity in BMMSCs directly contributes to malignant plasma cell phenotype in patients with MGUS and MM.
PADI2 citrullinates histone H3 at residue R26 within the promoter region of the IL-6 gene, which increases its expression and secretion. IL-6 can
then mediates its effects on other cells within the bone marrow, including the malignant plasma cells, which become more resistant to
chemotherapeutic agents, such as bortezomib.
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determinants in the BM that actually contribute to the progression
of this disease: whether these are active drivers, or release of
inhibitors of malignant progression.
Our data provide a mechanism by which IL-6 secretion is
increased in BMMSCs of patients, which may contribute to
treatment failure of bortezomib, a key therapeutic agent in MM
treatment strategies. It is important to note, however, that anti-
IL-6 therapy has not proven to be an efﬁcacious agent in MM thus
far, suggesting that targeting this signalling axis alone is likely to
be insufﬁcient to achieve clinical beneﬁt.43 PADI2 may therefore
represent a novel upstream target, as our data suggest that its
activity increases expression of other central signalling networks
between BMMSCs and myeloma cells, such as HGF-cMET and
CXCL12-CXCR4 (Figure 4b). PADIs are a family of enzymes, of
which PADI2 is becoming increasingly linked to a number of
chronic diseases, including cancer,27,44 rheumatoid arthritis,45
Alzheimer’s disease46 as well as autoimmune disease.47 Targets
of the PADI enzymes include proteins with diverse functions such
as extracellular matrix formation (for example, vimentin and
myelin) and chromatin structure (histone H3).24 Importantly, as
arginine citrullination is expected to be a relatively long-lived
post-translational modiﬁcation due to the absence of a char-
acterised peptidylcitrullinine iminotransferase, these modiﬁcations
may only be reversed through protein turnover. In the case of
histone H3R26 citrullination within the IL-6 promoter, this suggests
that the chromatin unwinding and activation induced by this
modiﬁcation may only be reversed through proliferation or
histone eviction. It is also highly likely that a much larger number
of pro-malignant transcripts are also modulated by the activity of
PADI2. Indeed, a previous study of the effect of PADI2 on
oestrogen receptor-mediated transcriptional regulation showed
that it regulated over 200 transcripts in those conditions.27 Future
work will focus on deﬁning more of these targets in BMMSCs in
order to determine the broader implications of PADI2 in the
transformation of the healthy BM to that of MGUS/MM.
Therapeutic targeting of PADI2 may therefore represent a good
(and early) therapeutic target in MGUS patients as well as those
with MM, which may act by removing a signiﬁcant proportion of
the supportive signalling required by malignant plasma cells for
survival and proliferation. Indeed, with the growing role for PADI2
in other chronic diseases, this enzyme may represent a novel
therapeutic target in many pathological conditions.
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